QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data supplement All Versions of this Article: jpet.105.096347v1 316/3/1080    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Waring, J. F. Articles by Roth, R. A. Search for Related Content PubMed PubMed Citation Articles by Waring, J. F. Articles by Roth, R. A.

TOXICOLOGY

Microarray Analysis of Lipopolysaccharide Potentiation of Trovafloxacin-Induced Liver Injury in Rats Suggests a Role for Proinflammatory Chemokines and Neutrophils

Department of Cellular and Molecular Toxicology, Abbott Laboratories, Abbott Park, Illinois (J.F.W., M.J.L., E.A.G.B.); Abbott Bioresearch Center, Worcester, Massachusetts (R.F.S.); and Department of Pharmacology and Toxicology, National Food Safety and Toxicology Center, Center for Integrative Toxicology, Michigan State University, East Lansing, Michigan (J.P.L., J.F.M., P.E.G., C.N., R.A.R.)

Idiosyncratic drug toxicity refers to toxic reactions occurring in a small subset of patients and usually cannot be predicted during preclinical or early phases of clinical trials. One hypothesis for the pathogenesis of hepatic idiosyncratic drug reactions is that, in certain individuals, underlying inflammation results in sensitization of the liver, such that injury occurs from an agent that typically would not cause hepatotoxicity at a therapeutic dose. We explored this possibility by cotreating rats with nonhepatotoxic doses of bacterial lipopolysaccharide (LPS) and trovafloxacin (TVX), a drug that caused idiosyncratic hepatotoxicity in humans. The combination of LPS and TVX resulted in hepatotoxicity in rats, as determined by increases in serum alanine aminotransferase activity and hepatocellular necrosis, which were not observed with either agent alone. In contrast, treatment with LPS and levofloxacin, a fluoroquinolone without human idiosyncratic liability, did not result in these changes. Liver gene expression analysis identified unique changes induced by the combination of TVX and LPS, including enhanced expression of chemokines, suggestive of liver neutrophil (PMN) accumulation and activation. Consistent with a role for PMN in the hepatotoxicity induced by LPS/TVX, prior depletion of PMN attenuated the liver injury. The results suggest that gene expression profiles predictive of idiosyncratic liability can be generated in rats cotreated with LPS and drug. Furthermore, they identify gene expression changes that could be explored as biomarkers for idiosyncratic toxicity and lead to enhanced understanding of the mechanism(s) underlying hepatotoxicity induced by TVX.

Address correspondence to: Dr. Jeffrey F. Waring, Molecular and Cellular Toxicology, Abbott Laboratories, Bldg. AP9A R463, 100 Abbott Park Road, Abbott Park, IL 60064-6104. E-mail: jeff.waring{at}abbott.com

This article has been cited by other articles:

				P. J. Shaw, P. E. Ganey, and R. A. Roth Tumor Necrosis Factor{alpha} Is a Proximal Mediator of Synergistic Hepatotoxicity from Trovafloxacin/Lipopolysaccharide Coexposure J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 62 - 68. [Abstract] [Full Text] [PDF]

				P. J. Shaw, A. C. Ditewig, J. F. Waring, M. J. Liguori, E. A. Blomme, P. E. Ganey, and R. A. Roth Coexposure of Mice to Trovafloxacin and Lipopolysaccharide, a Model of Idiosyncratic Hepatotoxicity, Results in a Unique Gene Expression Profile and Interferon Gamma-Dependent Liver Injury Toxicol. Sci., January 1, 2009; 107(1): 270 - 280. [Abstract] [Full Text] [PDF]

				X. Deng, M. J. Liguori, E. M. Sparkenbaugh, J. F. Waring, E. A. G. Blomme, P. E. Ganey, and R. A. Roth Gene Expression Profiles in Livers from Diclofenac-Treated Rats Reveal Intestinal Bacteria-Dependent and -Independent Pathways Associated with Liver Injury J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 634 - 644. [Abstract] [Full Text] [PDF]

				M. J. Liguori, E. A.G. Blomme, and J. F. Waring Trovafloxacin-Induced Gene Expression Changes in Liver-Derived in Vitro Systems: Comparison of Primary Human Hepatocytes to HepG2 Cells Drug Metab. Dispos., February 1, 2008; 36(2): 223 - 233. [Abstract] [Full Text] [PDF]

				J.-Z. Zhang and K. W. Ward Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes J. Antimicrob. Chemother., January 1, 2008; 61(1): 111 - 116. [Abstract] [Full Text] [PDF]

				P. J. Shaw, M. J. Hopfensperger, P. E. Ganey, and R. A. Roth Lipopolysaccharide and Trovafloxacin Coexposure in Mice Causes Idiosyncrasy-Like Liver Injury Dependent on Tumor Necrosis Factor-Alpha Toxicol. Sci., November 1, 2007; 100(1): 259 - 266. [Abstract] [Full Text] [PDF]